Esperion Therapeutics, Inc.
ESPREsperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Drugs in Pipeline
4
Phase 3 Programs
3
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How ESPR's past catalysts played out
Bempedoic Acid
Hyperlipidemias
Bempedoic acid 180 mg tablet
Cardiovascular Diseases
ETC-1002
Hyperlipidemia
bempedoic acid 180mg
Hypercholesterolemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Bempedoic Acid | Phase 3 | Hyperlipidemias | - | - |
Bempedoic acid 180 mg tablet | Phase 3 | Cardiovascular Diseases | - | - |
ETC-1002 | Phase 3 | Hyperlipidemia | - | - |
bempedoic acid 180mg | Phase 2 | Hypercholesterolemia | - | - |
Frequently asked questions
What is in Esperion Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Esperion Therapeutics, Inc.'s (ESPR) pipeline across Phase 3, Phase 2. Its lead program is Bempedoic Acid (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Esperion Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Esperion Therapeutics, Inc. (ESPR) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ESPR biotech catalysts?→
Add ESPR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Esperion Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.